Predictive factors of response to anthracylines neoadjuvant chemotherapy in breast cancer;Chimiothérapie néoadjuvante par anthracyclines dans le cancer du sein : facteurs prédictifs de réponse

Gynecologie Obstetrique et Fertilite

Volumn 39, Issue 2, 2011, Pages 81-86

  Bensouda, Y ^a   Ismaili, N ^a   Ahbeddou, N ^a   El Hassani, K ^a   Chenna, M ^b   Sbitti, Y ^a   Boutayeb, S ^a   Errihani, H ^a  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Morocco)

^b IBN SINA HOSPITAL   (Morocco)

Author keywords

Anthracyclines; Breast cancer; Neoadjuvant chemotherapy; Pathologic complete response (pCR); Predictive factors

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HORMONE RECEPTOR;

ADULT; ARTICLE; BREAST CANCER; CANCER GRADING; HUMAN; HUMAN TISSUE; LYMPH NODE; MAJOR CLINICAL STUDY; TREATMENT RESPONSE;

EID: 79952191665     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2010.12.004     Document Type: Article

References (73)

1. A. Belot, P. Grosclaude, N. Bossard, E. Jougla, E. Benhamou, and P. Delafosse Cancer incidence and mortality in France over the period 1980-2005 Rev Epidemiol Sante Publique 56 3 2008 159 175
2. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and T. Murray Cancer statistics 2008 CA Cancer J Clin 58 2 2008 71 96
3. J.A. Van der Haje, C.J. van de Velde, J.P. Julien, M. Tubiana-Hulin, C. Vandervelden, and L. Duchateau Preoperative chemotherapy in primary operable breast cancer, results from the European Organization for Research and Treatment of Cancer Trial 10902 J Clin Oncol 19 2001 4224 4237 (Pubitemid 33081640)
4. G. Bonadonna, P. Valagussa, C. Brambilla, L. Ferrari, A. Moliterni, and M. Terenziani Primary chemotherapy in operable breast cancer eight year experience at the Milan Cancer Institute J Clin Oncol 16 1998 93 100 (Pubitemid 28041584)
5. S. Chua, I.E. Smith, R. A'Hern, G. Coombes, T.F. Hickish, and A.C. Robinson TOPIC Trial Group. Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2) Ann Oncol 16 9 2005 1435 1441 (Pubitemid 41222415)
6. M.T. Laloni, F. Moura Silva, and C. Tosello A randomized neoadjuvant chemotherapy (NC) study in advanced breast cancer (BC): AC vs FEC 60 J Clin Oncol 22 14S 2004 832 [ASCO Annual Meeting; Abstract]
7. A. Buzdar, S.E. Singletary, R. Theriault, D.J. Booser, V. Valero, and N. Ibrahim Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer J Clin Oncol 17 1999 3412 3417 (Pubitemid 29517908)
8. V. Dieras, P. Fumoleau, G. Romieu, M. Tubiana-Hulin, M. Namer, and L. Mauriac Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatments of patients with breast cancer J Clin Oncol 22 24 2004 4958 4965 (Pubitemid 46638621)
9. V.F. Semiglazov, A.A. Bojok, and A.S. Arsumanov Breast conserving surgery after neoadjuvant chemotherapy paclitaxel + doxorubicln vs fluorouracil + doxorubicin + cyclophosphamide in locally advanced breast cancer Br Cancer Res Treat 76 Suppl. 1 2002 159 [Abstract]
10. B Fisher, A. Brown, E. Mamounas, S. Wieand, A. Roidoux, and Margolese Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. (NSABP-B18) J Clin Oncol 15 7 1997 2483 2493 (Pubitemid 27289876)
11. B. Fisher, J. Bryant, N. Wolmark, E. Mamounas, A. Brown, and E.R. Fisher Effect of preoperative chemotherapy on the outcome of women with operable breast cancer J Clin Oncol 16 8 1998 2672 2685 (Pubitemid 28363030)
12. N. Wolmark, J. Wang, E. Manounas, J. Bryant, and B. Fisher Preoperative chemotherapy in patients with operable breast cancer: nine-year results from NSABP-B18 J Natl Cancer Inst Monogr 30 2001 96 102
13. P. Rastogi, S.J. Anderson, H.D. Bear, C.E. Geyer, M.S. Kahlenberg, and A. Robidoux Preoperative chemotherapy: updates of National Surgical, Adjuvant Breast and Bowel Project Protocols B-18 and B-27 J Clin Oncol 26 5 2008 778 785 Erratum in: J Clin Oncol. 2008;26(16):2793 (Pubitemid 351264391)
14. D. Munoz Gonzalez, I. Zeichner-Gancz, M. Candelaria, M.T. Ramirez-Ugalde, M. Perez-Sanchez, and G. Cervantes-Vazquez Her-2/neu expression as a predictive factor for response to anthracycline-based chemotherapy in a Mexican population of locally advanced breast cancer patients Med Oncol 22 1 2005 23 28 (Pubitemid 40647226)
15. C. Gajdos, P.I. Tartter, A. Estabrook, M.A. Gistrak, S. Jaffer, and I.J. Bleiweiss Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer J Surg Oncol 80 1 2002 4 11 (Pubitemid 34477727)
16. K.M. Kling, N. Ostrzega, and P. schmit Breast conservation after induction chemotherapy for locally advanced breast cancer Clin Cancer Res 3 4 1997 593 600
17. L. Mauriac, G. Mac Grogan, A. Avril, M. Durand, A. Floquet, and M. Debled Institut Bergonie Bordeaux Groupe Sein (IBBGS). Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicenter randomized trial with 124-month median follow-up Ann Oncol 10 1 1999 47 52 (Pubitemid 29090591)
18. H.M. Kuerer, L.A. Newman, T.L. Smith, F.C. Ames, K.K. Hunt, and K. Dhingra Clinical course of breast cancer patients with complete pathologic primary tumour and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy J Clin Oncol 17 2 1999 460 469 (Pubitemid 29075229)
19. P. Chollet, S. Amat, H. Cure, M. de Latour, G. Le Bouedec, and M.A. Mouret-Reynier Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer Br J Cancer 86 2002 1041 1046 (Pubitemid 34441058)
20. R. Vyzula, L. Dusek, J. Zaloudik, R. Demlová, D. Klimes, and S. Selvekerová Breast cancer and neoadjuvant therapy: any predictive marker? Neoplasma 51 6 2004 471 480 (Pubitemid 40052916)
21. G. Von Minckwitz, S. Costa, G. Raab, J.U. Blohmer, H. Eidtmann, and J. Hilfrich Dose-dense doxorubicin, docetaxel, and granulocyte colony-stimulating factor support with or without tamoxifen as preoperative therapy in patients with operable carcinoma of the breast: a randomized, controlled, open phase IIb study J Clin Oncol 15 2001 3506 3515 (Pubitemid 32730088)
22. V.F. Cocquyt, V.R. Schelfhout, P.N. Blondeel, H.T. Depypere, K.K. Daems, and R.F. Serreyn The role of biological markers as predictors of response to preoperative chemotherapy in large primary breast cancer Med Oncol 20 3 2003 221 231 (Pubitemid 37193933)
23. M.C. Mathieu, R. Rouzier, A. Llombart-Cussac, L. Sideris, S. Koscielny, and J.P. Travagli The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile Eur J Cancer 40 3 2004 342 351 (Pubitemid 38121270)
24. M. Cristofanilli, A. Gonzalez-Angulo, N. Sneige, S.W. Kau, K. Broglio, and R.L. Theriault Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes J Clin Oncol 23 2005 41 48 (Pubitemid 41702621)
25. T. Petit, M. Wilt, M. Velten, R. Millon, J.F. Rodier, and C. Borel Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy Eur J Cancer 40 2 2004 205 211 (Pubitemid 38077022)
26. S. Amat, F. Penault-Llorca, H. Cure, G Le Bouedëc, J.L. Achard, and I. Van Praagh Scarff-Bloom-Richardson (SBR) grading: a pleiotropic marker of chemosensitivity in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy Int J Oncol 20 4 2002 791 796
27. I.F. Faneyte, J.G. Schrama, J.L. Peterse, P.L. Remijnse, S. Rodenhuis, and M.J. van de Vijver Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 3 2003 406 412 (Pubitemid 36308152)
28. L. Gianni First report of the European Cooperative Trial in Operable breast cancer (ECTO): effects of primary systemic therapy (PST) on local-regional disease Proc Am Soc Clin Oncol 21 34a 2002 132 [Abstract]
29. V. Stearns, B. Singh, T. Tsangaris, J.G. Crawford, A. Novielli, and M.J. Ellis A prospective randomized pilot study to evaluate predictors of response in serial core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients with locally advanced breast cancer Clin Cancer Res 9 1 2003 124 133 (Pubitemid 36109724)
30. Y. Remvikos, M. Jouve, P. Beuzedoc, P. Viehl, H. Magdelenat, and P. Pouillart Cell cycle modifications of breast cancers during neoadjuvant chemotherapy: a flow cytometry study on fine needle aspirates Eur J Cancer 13 1993 1843 1848 (Pubitemid 23288025)
31. S. Chevillard, P. Pouillart, C. Beldjord, B. Asselain, P. Beuzeboc, and H. Magdelénat Sequential assessment of multidrug resistance phenotype and measurement of S-phase fraction as predictive markers of breast cancer response to neoadjuvant chemotherapy Cancer 77 1996 292 300 (Pubitemid 26023348)
32. M. Colleoni, I. Minchella, G. Mazzarol, F. Nol, G. Peruzzotti, and A. Rocca Response to primary chemotherapy in breast cancer with tumours not expressing oestrogen and progesterone receptors Ann Oncol 11 2000 1057 1059
33. D. Kandioler, C. Ludwing, M. Rudas, S. Kappel, E. Janschek, and C. Wenzel TP53 mutation and p53 overexpression for prediction of response to neoadjuvant treatment in breast cancer patients Clin Cancer Res 6 1 2000 50 56 (Pubitemid 30064975)
34. G. Mac Grogan Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection oh hormonal receptors, p53, cerbB-2, MiB1, pS2 and GST pi Br J Cancer 74 9 1996 1458 1465 (Pubitemid 26370740)
35. A.U. Buzdar, V. Valero, and R.L. Theriault Pathological complete response to chemotherapy is related to hormone receptor status Breast Cancer Res Treat 82 Suppl. 1 2003 302 [Abstract]
36. J. Chang, T.J. Powles, D.C. Alfred, S.E. Ashley, G.M. Clark, and A. Makris Biologic markers as predictors of clinical outcome fro systemic therapy from primary operable breast cancer J Clin Oncol 17 1999 3058 3063 (Pubitemid 29470633)
37. A.E. Ring, I.E. Smith, S. Ashley, L.G. Fulford, and S.R. Lakhani Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer Br J Cancer 91 12 2004 2012 2017 (Pubitemid 40128767)
38. M. Campiglio, G. Somenzi, C. Olgiati, G. Beretta, A. Balsari, and N. Zaffaroni Role of proliferation in HER2 status predicted response to doxorubicin Int J Cancer 105 4 2003 568 573 (Pubitemid 36578565)
39. C. Abrial, F. Bouchet-Mishellany, I. Raoelfils, A. Cayre, H. Curé, and P. Chollet Place of anatomopathology in evaluation of response to neoadjuvant chemotherapy. Prognostic and predictive markers: example of breast cancer Bull Cancer 93 7 2006 663 668
40. V. Guarneri, K. Broglio, S.W. Kau, M. Cristofanilli, A.U. Buzdar, and V. Valero Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors J Clin Oncol 24 7 2006 1037 1044 (Pubitemid 46638799)
41. C. Wenzel, D. Hussian, R. Bartsch, U. Pluschnig, G.J. Locker, and M. Rudas Preoperative therapy with epidoxorubicin and docetaxel plus trastuzumab in patients with primary breast cancer: a pilot study J Cancer Res Clin Oncol 130 7 2004 400 404 (Pubitemid 39044342)
42. F.M. Penault-Llorca, S. Amat, and M. De Latour Scarff-Bloom-Richardson (SBR) grading: from predictive to prognostic significance in invasive ductal breast carcinomas treated by neoadjuvant chemotherapy (CT) Br Cancer Res Treat 76 2002 153 [Abstract]
43. G. Aftimos, V. Trak-Smayra, and Moacdieh-Reyahel Breast cancer: prognostic value of flow cytometry and hormone receptors. Apropos of a Lebanese series of patients J Med Liban 48 1 2000 8 17 (Pubitemid 30421672)
44. A. Makris, T.J. Powles, M. Dowsett, C.K. Osborne, P.A. Trott, and I.N. Fernando Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas Clin Cancer Res 3 1997 593 600 (Pubitemid 27211838)
45. R.J. Burcombe, A. Makris, P.I. Richman, F.M. Daley, S. Noble, and M. Pittam Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer Br J Cancer 92 2005 147 155 (Pubitemid 40188448)
46. S. Kariya, Y. Ogawa, A. Nishioka, T. Moriki, T. Ohnishi, and S. Ito Relationship between hormonal receptors, HER-2, p53 protein, Bcl-2, and MIB-1 status and the antitumor effects of neoadjuvant anthracycline-based chemotherapy in invasive breast cancer patients Radiat Med 23 3 2005 189 194 (Pubitemid 40874480)
47. F. Penault-Llorca, A. Cayre, Bouchet Mishellany, S. Amat, V. Feillel, and G. Le Bouedec Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome Int J Oncol 22 6 2003 1319 1325
48. G.G. Steger, C. Wenzel, and M. Schmidinger Predictive factors of complete pathological response in primary breast cancer treated neoadjuvantly with epirubicin/taxane + G-CSF regimen Proc Am Soc Clin Oncol 20 39 2001 154 [Abstract]
49. F. Zhang, L. Pusztai, and Y. Yang Correlation between HER2 expression of breast cancer and response to neoadjuvant FAC chemotherapy Proc Am Soc Clin Oncol 21 32a 2002 124 [Abstract]
50. C. Lovekin, I.O. Ellis, A. Locker, J.F. Robertson, J. Bell, and R. Nicholson c-erbB-2 oncoprotein expression in primary and advanced breast cancer Br J Cancer 63 3 1991 439 443
51. K.I. Pritchard, H. Messersmith, L. Elavathil, M. Trudeau, F. O'Malley, and B. Dhesy-Thind HER-2 and topoisomerase II as predictors of response to chemotherapy J Clin Oncol 26 5 2008 736 744 Review (Pubitemid 351264386)
52. T. Aas, S. Geisler, G.E. Eide, D.F. Haugen, J.E. Varhaug, and A.M. Bassøe Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy Eur J Cancer 39 4 2003 438 446 (Pubitemid 36173687)
53. S. Lizard-Nacol, B. Coudert, and J.M. Riedinger P53 gene alterations are associated with a decreased responsiveness to neoadjuvant chemotherapy in human breast cancer Int J Oncol 10 1997 1202 1207
54. S. Geisler, P.E. Lonning, T. Aas, H. Johnsen, O. Fluge, and D.F. Haugen Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer Cancer Res 61 2001 2505 2512 (Pubitemid 32685830)
55. P. Bertheau, F. Plassa, M. Espié, E. Turpin, A. de Roquancourt, and M. Marty Effect of mutated TP53 on response of advanced beast cancers to high dose chemotherapy Lancet 360 2002 852
56. Y. Xu, L. Yao, T. Ouyang, L. Yao, T. Ouyang, and J. Li p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer Clin Cancer Res 11 20 2005 7328 7333 (Pubitemid 41507691)
57. P. Collechi, E. Baldini, P. Giannessi, A.G. Naccarato, A. Passoni, and G. Gardin Primary chemotherapy in locally advanced breast cancer (LABC): effects on tumour proliferative activity, b-cl2 expression and the relationship between tumour regression and biological markers Eur J Cancer 34 11 1998 1701 1704 (Pubitemid 28474222)
58. J.S. Coon, E. Marcus, S. Gupta-Burt, S. Seelig, K. Jacobson, and S. Chen Amplification and overexpression of topoisomerase II alpha predict response to anthracycline-based therapy in locally advanced breast cancer Clin Cancer Res 8 4 2002 1061 1067 (Pubitemid 35177356)
59. M. Martin-Richard, M. Munoz, J. Albanell, L. Colomo, M. Bellet, and M.J. Rey Serial topoisomerase II expression in primary breast cancer and response to neoadjuvant anthracycline-based chemotherapy Oncology 66 5 2004 388 394 (Pubitemid 39194361)
60. A. Di Leo, and J. Isola Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin Breast Cancer 4 3 2003 179 186 (Pubitemid 37185053)
61. V. Durbecq, M. Paesmans, F. Cardoso, C. Desmedt, A. Di Leo, and S. Chan Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel Mol Cancer Ther 3 10 2004 1207 1214 (Pubitemid 39440165)
62. T.A. Buchholz, D.N. Stiver, J. Stec, H.M. Kuerer, G.N. Hortobagyi, and L. Pusztai Global gene expression changes during neoadjuvant chemotherapy for human breast cancer Cancer J 8 6 2002 461 468
63. L. Pusztai, M. Ayers, J. Stec, E. Clark, K. Hess, and D. Stivers Emerging science: prospective validation of gene expression profiling-based prediction of complete pathologic response to neoadjuvant paclitaxel/FAC chemotherapy in breast cancer Proc Am Soc Clin Oncol 22 1 2003 1 [Abstract]
64. M. Ayers, W.F. Symmans, J. Stec, A.I. Damokosh, E. Clark, and K. Hess Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer J Clin Oncol 22 12 2004 2284 2293 (Pubitemid 41115384)
65. T. Nishidate, T. Katagiri, M.L. Lin, Y. Mano, Y. Miki, and F. Kasumi Genome wide gene-expression profiles of breast-cancer cells purified with laser microbeam microdissection: identification of genes associated with progression and metastasis Int J Oncol 25 4 2004 797 819
66. J.C. Chang, E.C. Wooten, A. Tsimelzon, S.G. Hilsenbeck, M.C. Gutierrez, and Y.L. Tham Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients J Clin Oncol 23 6 2005 1169 1177 (Pubitemid 46202273)
67. F. Bertucci, P. Finetti, J. Rougemont, E. Charafe-Jauffret, V. Nasser, and B. Loriod Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy Cancer Res 64 23 2004 8558 8565 (Pubitemid 39552068)
68. L. Gianni, M. Zambetti, K. Clark, J. Baker, M. Cronin, and J. Wu Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer J Clin Oncol 23 29 2005 7265 7277 (Pubitemid 46202341)
69. M.J. Van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, and D.W. Voskuil A gene-expression signature as a predictor of survival in breast cancer N Engl J Med 347 25 2002 1999 2009 (Pubitemid 35461656)
70. S. Paik, S. Shak, G. Tang, C. Kim, J. Baker, and M. Cronin A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer N Engl J Med 351 27 2004 2817 2826 (Pubitemid 40051905)
71. C.M. Perou, T. Sørlie, M.B. Eisen, M. van de Rijn, S.S. Jeffrey, and C.A. Rees Molecular portraits of human breast tumours Nature 406 6797 2000 747 752
72. R. Rouzier, C.M. Perou, W.F. Symmans, N. Ibrahim, M. Cristofanilli, and K. Anderson Breast cancer molecular subtypes respond differently to preoperative chemotherapy Clin Cancer Res 11 16 2005 5678 5685 (Pubitemid 41170290)
73. Marty M, Guinebretiere JM, Mathieu MC, Sigal-Zafrani B, de Roquancourt A, Spielmann M, et al. Sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients: results of the planned interim analysis and analysis of predictive parameters. San Antonio Breast Cancer (SABC); 2007 [Abstract 5058]